Objective To investigate the serum levels of IL‐23 and IL‐17A in relapsing remitting multiple sclerosis (RRMS) patients after methylprednisolone pulse therapy .Methods ELISA method was used to detect the levels of IL‐23 and IL‐17A and the positive rate (450 nm D value 2.1 times more than the negative control D value both before and after treatment was defined as positive ,the positive rate= positive cases/total number of cases multiplied by 100% ) in 24 cases of RRMS patients before and after corticosteroid therapy (1.0 g ,intravenous drip per day for three days and 0.5 g intravenous drip per day in the next 4 days) and 20 cases with non‐inflammatory diseases of nervous system (NIDNS) patients .Results The detection rate of IL‐23 and IL‐17A in the RRMS group was significantly higher than the NIDNS group (IL‐23 :79.17% vs .35.00% ,χ2 =7.071 ,P=0.008 ;IL‐17A :83.33% vs .30.00% ,χ2 =10.725 ,P=0.001);The levels of IL‐23 and IL‐17A descended in serum of RRMS patients after methylprednisolone pulse therapy [IL‐23:(382.4 ± 124.7) pg/mL vs .(610.6 ± 102.5) pg/mL ,t=14.672 ,P=0.000 ;IL‐17A :(32.8 ± 20.2) pg/mL vs .(74.6 ± 21.7) pg/mL , t=11.108 ,P=0.000] , but were still much higher than those in the NIDNS group [IL‐23 :(88.7 ± 8.4) pg/mL ,t=10.344 ,P=0.000 ;IL‐17A :(18.1 ± 0.9) pg/mL ,t=9.205 ,P=0.000] .Conclusions IL‐23 and IL‐17A are associated with the pathogenesis of MS .Methylprednisolone pulse therapy can reduce the levels of IL‐23 and IL‐17A in sera of RRMS patients .%目的：探讨甲泼尼龙（MP）冲击治疗对复发缓解型多发性硬化（RRMS）患者血清中IL‐23和IL‐17A水平的影响。方法选择24例 RRMS患者（RRMS组）及20例神经系统非炎性疾病患者（NIDNS 组），采用ELISA方法检测MP冲击治疗（1.0 g 静脉滴注1次／d ×3，之后0.5 g 静脉滴注1次／d ×4）前后血清中IL‐23、IL‐17A的水平并计算阳性检出率〔以治疗前后450 nm处 D（λ）值均为阴性对照D（λ）值的2.1倍以上者为阳性，阳性检出率＝阳性例数／总例数×100％〕。结果 RRMS组IL‐23和 IL‐17A阳性检出率明显高于 NIDNS组（IL‐23：79.17％ vs ．35.00％，χ2＝7.071，P＝0.008；IL‐17A ：83.33％ vs ．30.00％，χ2＝10.725，P＝0.001）；RRMS组治疗后血清中IL‐23、IL‐17A水平〔分别（382.4±124.7） pg／mL ；（32.8±20.2） pg／mL〕较治疗前〔分别（610.6±102.5） pg／mL ；（74.6±21.7） pg／mL〕明显下降（IL‐23：t＝14.672，P＝0.000；IL‐17A ：t＝11.108，P＝0.000），但仍高于NIDNS 组〔IL‐23：（88.7±8.4） pg／mL ，t＝10.344，P＝0.000；IL‐17A ：（18.1±0.9） pg／mL ，t＝9.205，P＝0.000〕。结论 IL‐23和IL‐17A可能与MS发病有关，MP冲击治疗可降低RRMS患者血清中IL‐23和IL‐17A水平。
展开▼
